Shah Capital, a top shareholder of Novavax (NASDAQ:NVAX), has withdrawn its proxy campaign against the company days after the ...
Novavax (NVAX) stock surged after reaching a licensing agreement with Sanofi (SNY) for its COVID-19 vaccine and Matrix-M adjuvant. Read more here.
The recent run of good fortune for vaccine maker Novavax (NASDAQ:NVAX continues. Following the major licensing deal with ...
Shah Capital Management has withdrawn a proxy campaign against the re-election of directors at vaccines firm Novavax in the ...
Novavax will only be able to offer a COVID-19 vaccine in the United States this autumn if regulators accept the shot it has ...
If you'd invested $10,000 in Novavax a year ago, right now, you'd have $15,200. And here's even better news: The Sanofi ...
Novavax will only be able to offer a COVID-19 vaccine in the United States this autumn if regulators accept the shot it has ...
The COVID-19 vaccine was worth tens of billions of dollars, but most of it went into the hands of Moderna and Pfizer. Smaller ...
Novavax (NVAX) surges after one of its top shareholders drops a proxy campaign against the company. This withdrawal is in ...
The Biden administration's new tariffs on Chinese electric vehicles and other strategic sectors aim to protect the future of ...
In the stock market, a back-from-the-dead story is equally appealing. Stocks that have been left for dead, or at least seen ...